CASI Pharmaceuticals (CASI.US): The 2024 Q1 financial report achieved revenue of US$3.409 million, with a previous value of US$8.347 million, with an expected value of US$12 million; earnings per share were -0.71 dollars, the previous value was -0.45 US dollars, and the expected value was -0.05 US dollars.
CASI Pharmaceuticals(CASI.US)：2024年Q1财报实现营收340.9万美元，前值为834.7万美元，预期值为1200万美元；每股收益为-0.71美元，前值为-0.45美元，预期值为-0.05美元。
CASI Pharmaceuticals (CASI.US): The 2024 Q1 financial report achieved revenue of US$3.409 million, with a previous value of US$8.347 million, with an expected value of US$12 million; earnings per share were -0.71 dollars, the previous value was -0.45 US d
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated